ASCO 2018: Relapsed/Refractory Patients With Indolent Non-Hodgkin Lymphoma Responding to New Treatment, Regardless of Number of Prior Therapies
Ongoing MAGNIFY study shows promising results for lenalidomide plus rituximab combination therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.